Monoclonal antibody: The corner stone of modern biotherapeutics

Yaoxue Xuebao

Volumn 47, Issue 10, 2012, Pages 1275-1280

  Xia, Zhi Nan ^a   Cai, Xue Ting ^b   Cao, Peng ^b  

^a R and D Synageva Biopharma Corporation   (United States)

^b Jiangsu Province Institute of Traditional Chinese Medicine   (China)

Author keywords

Biobetter; Biosimilar; Biotherapeutic; Monoclonal antibody

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BELIMUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANAKINUMAB; CATUMAXOMAB; CD20 ANTIGEN; CENTOXIN; CERTOLIZUMAB PEGOL; CETUXIMAB; CHIMERIC ANTIBODY; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GANITUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; PENDING; RANIBIZUMAB; RITUAN; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VASCULOTROPIN;

ALLERGIC ASTHMA; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BIOLOGICAL THERAPY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER RECURRENCE; CHINESE HAMSTER; CHO CELL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG MANUFACTURE; DRUG MARKETING; DRUG TARGETING; ESCHERICHIA COLI; EUROPEAN UNION; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; GRAFT REJECTION; HEAD AND NECK CANCER; HEMOLYTIC UREMIC SYNDROME; HUMAN; ISOTOPE LABELING; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CANCER; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKEMIA; LUNG CANCER; LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHUMAN; OVARY CANCER; PANCREAS ISLET TRANSPLANTATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; T CELL LYMPHOMA; ULCERATIVE COLITIS; UNITED STATES;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; EUROPEAN UNION; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871189298     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Reichert JM. Antibody-based therapeutics to watch in 2011 [J]. MAbs, 2011, 3: 76-99.
2. Reichert JM. Metrics for antibody therapeutics development [J]. MAbs, 2010, 2: 695-700.
3. Reichert JM. Antibodies to watch in 2010 [J]. MAbs, 2010, 2: 84-100.
4. Reichert JM. Marketed therapeutic antibodies compendium [J]. MAbs, 2012, 4: 413-415.
5. Beck A, Wurch T, Bailly C, et al. Strategies and challenges for the next generation of therapeutic antibodies [J]. Nat Rev Immunol, 2010, 10: 345-352.
6. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies [J]. Bioconjug Chem, 2010, 21: 5-13.
7. Mueller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy [J]. Biodrugs, 2010, 24: 89-98.
8. Royston I, Ho M, Beck A. Monoclonal antibody therapy [R]. Boston: Protein Engineering Summit, 2012: 212.
9. Jostock T. Expression of antibody in mammalian cells [M]// Al-Rubeai M. Antibody Expression and Production. New York: Springer, 2011: 1-24.
10. Payne T. Biosimilar draft guidance issue by US FDA [J]. Bioanalysis, 2012, 4: 759.
11. Berk A, Sanglier CS, Van DA. Biosimilar, Biobetter, and next generation antibody characterization by mass spectrometry [J]. Anal Chem, 2012, 84: 4637-4646.
12. Mullard A. Can next-generation antibodies offset biosimilar competition? [J]. Nat Rev Drug Discov, 2012, 11: 426-428.